Vasomune Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases associated with vascular dysfunction, made an important announcement today that the first patient has been admitted in the Phase 2a clinical study. This study will be pivotal iin evaluating AV-001 in hospitalized patients experiencing severe symptoms COVID-19 disease.
https://youtu.be/y_aTLqPAtfI?si=jeWWf4vVakZhmbu4
Vasomune Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases associated with vascular dysfunction, made an important announcement today that the first patient has been admitted in the Phase 2a clinical study. This study will be pivotal iin evaluating AV-001 in hospitalized patients experiencing severe symptoms COVID-19 disease.
Vasomune Therapeutics, Inc.は、血管機能障害に関連する疾患の治療薬開発に特化した臨床段階のバイオ製薬会社であり、本日、臨床第2a相試験において最初の患者が入院したことを発表しました。本試験は、重篤な COVID-19 疾患の入院患者を対象に AV-001 を評価する極めて重要な試験となります。